A comparative analysis of human and mouse islet G-protein coupled receptor expression

Stefan Amisten1, Patricio Atanes2, Ross Hawkes1, Inmaculada Ruiz-Maldonado1, Bo Liu1, Fariborz Parandeh2, Min Zhao1, Guo Cai Huang1, Albert Salehi2 & Shanta J. Persaud1

G-protein coupled receptors (GPCRs) are essential for islet function, but most studies use rodent islets due to limited human islet availability. We have systematically compared the GPCR mRNA expression in human and mouse islets to determine to what extent mouse islets can be used as surrogates for human islets to study islet GPCR function, and we have identified species-specific expression of several GPCRs. The A3 receptor (ADORA3) was expressed only in mouse islets and the A3 agonist MRS 5698 inhibited glucose-induced insulin secretion from mouse islets, with no effect on human islets. Similarly, mRNAs encoding the galanin receptors GAL1 (GALR1), GAL2 (GALR2) and GAL3 (GALR3) were abundantly expressed in mouse islets but present only at low levels in human islets, so that it reads (GALR3) and galanin inhibited insulin secretion only from mouse islets. Conversely, the sst1 receptor (SSTR1) was abundant only in human islets and its selective activation by CH 275 inhibited insulin secretion from human islets, with no effect on mouse islets. Our comprehensive human and mouse islet GPCR atlas has demonstrated that species differences do exist in islet GPCR expression and function, which are likely to impact on the translatability of mouse studies to the human context.

It is well-established that secretion of hormones from islets of Langerhans is regulated by activation of islet cell G-protein coupled receptors (GPCRs) by neurotransmitters, paracrine actions of islet hormones themselves, excluding insulin which acts through a tyrosine kinase receptor, and by circulating hormones1. Thus, it has been known for many years that parasympathetic and sympathetic neurotransmitters act at specific muscarinic and adrenergic GPCR subtypes to potentiate and inhibit the stimulatory effects of nutrients on insulin secretion, to allow fine-tuning of the insulin secretory response2. In addition, glucagon stimulates insulin and somatostatin release, while somatostatin inhibits glucagon and insulin release3. Furthermore, GLP-1, an incretin released from the gastrointestinal tract following food intake, acts at GPCRs on islet β- and α-cells to stimulate insulin and inhibit glucagon secretion4, and GIP, another incretin, also potentiates glucose-induced insulin release. The GLP-1 receptor is probably the most well characterised of all islet GPCRs, and several GLP-1 receptor agonists and DPP4 inhibitor drugs that stabilise incretin levels are in widespread clinical use as therapies for type 2 diabetes (T2D)3. A number of other GPCRs, including GPR119, FFAR1, GPRC5B and GPRC5C, all of which are expressed by human islets1, have also emerged as drug target candidates for the treatment of T2D6,7.

In addition to the reasonably well-characterised GPCRs, some of which are outlined above, human islets express almost 300 additional GPCRs1,8,9, but most of these have poorly characterised roles in islet physiology1. Due to the limited availability of human islets, the vast majority of all physiological and pharmacological studies on the regulation of islet hormone secretion have been carried out using isolated rodent islets, particularly from a variety of mice strains. Although islets are readily available from both normal and transgenic mice, it is unclear to what extent data obtained by studying rodent islet function are translatable to the human context. In fact, mouse and human islets have distinct morphological arrangements, which may impact on their function10,11 and several studies comparing the gene expression profiles of human and rodent islets suggest that there are significant differences, including in GPCR expression12–14. This has been confirmed functionally in experiments using isolated rodent and human islets where it has been reported that human islets express β-adrenergic receptors that are coupled to elevation of insulin secretion, while β-adrenergic agonists have no effect on insulin release from rat islets15.

1Diabetes Research Group, Division of Diabetes & Nutritional Sciences, Faculty of Life Sciences & Medicine, King’s College London, London, UK. 2Department of Clinical Science, Division of Islet Cell Physiology, SUS, University of Lund, Malmö, Sweden. Correspondence and requests for materials should be addressed to S.A. (email: stefan.amisten@kcl.ac.uk) or S.J.P. (email: shanta.persaud@kcl.ac.uk)
In addition, MT1 receptors, which are activated by the pineal hormone melatonin, are reported to be expressed by rodent β-cells but not by human β-cells, and different classes of purinergic receptor regulate intracellular calcium levels in rodent and human β-cells.

To date there has not been a systematic review of the GPCR gene expression repertoires of rodent and human islets, so in the current study we have compared human islet GPCR mRNA profiles with those of islets isolated from outbred ICR mice and inbred C57BL/6 mice. We have used these data to identify a core set of GPCRs that are expressed in both human and mouse islets, as well as islet GPCRs that show species-restricted expression. The extensive GPCR gene expression profiles presented here will provide the scientific community with a comprehensive comparative analysis of the mRNA expression of all functional human GPCRs and their mouse orthologues in human and mouse islets. This can then be used as a reference tool for the translation of mouse islet functional GPCR data to the human context, which will facilitate the evaluation of islet GPCRs as drug target candidates for novel diabetes therapies.

Results

Expression of GPCR mRNAs in islets isolated from C57 and ICR mice. The qPCR analyses indicated that transcripts encoding 183 GPCRs of the 341 GPCR mRNAs analysed (53.7%) were expressed at levels greater than 0.001% of the mean mRNA expression of the reference genes Actb, Gapdh, Ppia, Tbp and Tfrc in islets isolated from ICR and C57 mice. The remaining 158 GPCR mRNAs were either absent or expressed only at exceedingly low levels (<0.001% of the mean mRNA expression of the reference genes) in both mouse strains.

It can be seen from Fig. 1 that the overall islet GPCR mRNA expression profiles in outbred ICR mice and inbred C57BL/6 mice. We have used these data to identify a core set of GPCRs that are expressed in both human and mouse islets, as well as islet GPCRs that show species-restricted expression. The extensive GPCR gene expression profiles presented here will provide the scientific community with a comprehensive comparative analysis of the mRNA expression of all functional human GPCRs and their mouse orthologues in human and mouse islets. This can then be used as a reference tool for the translation of mouse islet functional GPCR data to the human context, which will facilitate the evaluation of islet GPCRs as drug target candidates for novel diabetes therapies.

Strain-specific expression of GPCR mRNAs in mouse islets. 154 of the 183 GPCR mRNAs that were detected above trace levels were commonly expressed by both ICR and C57 islets, indicating that there are striking similarities in islet GPCR expression between the two mouse strains. In fact, ICR and C57 mouse islets shared eight out of ten of their most abundantly expressed GPCR mRNAs (Cacrl, Cckar, Ffar1, Galr1, Glp1r, Gpr158, Gpr56 and Gpcr5c; Fig. 2a,b), suggesting that these GPCRs play important roles in the normal function of mouse islets. However, we did identify some strain-specific differences in GPCR mRNA expression such that 12 GPCR mRNAs were expressed only by C57 islets while 17 additional GPCR mRNAs were only detected in ICR islets (Supplementary Table 1).

Comparative analysis of GPCR mRNA expression by human and mouse islets. The relative expression of the ten most abundant GPCR mRNAs in human and mouse islets are presented in Fig. 2a–c. These figures indicate that while there was a high level of concordance between the mouse strains, as described above,
only three of the ten most highly expressed human islet GPCR mRNAs were common to the ten most abundant mouse islet GPCR mRNAs. Nonetheless, in both mouse and human islets, the adhesion receptor GPR56 was the most abundantly expressed GPCR mRNA, with mRNA levels at ~20% and 50% of the mean mRNA expression of the five reference genes in human islets and mouse islets respectively. The GLP-1 receptor, which is the target for incretin mimetic therapies for type 2 diabetes that are known to stimulate insulin secretion in rodents and humans\(^\text{19}\), was another abundant GPCR in human and mouse islets. The third highly expressed GPCR mRNA common to human and mouse islets was FFAR1, which is activated by long chain fatty acids. The receptors identified in Fig. 2a–c were all expressed at >5% of the mean mRNA expression levels of the five reference genes and represented the most abundant GPCRs. However, overall the mean mRNA expression of all quantifiable islet GPCRs, relative to the reference genes, was 0.53% in human islets (206 GPCRs) and 1.4% in mouse islets (1.34% in ICR mouse islets; 167 GPCRs and 1.37% in C57 islets; 163 GPCRs). Thus, although there are a large number of GPCR mRNAs expressed by mouse and human islets, the majority of them are of low abundance. Expression of all human GPCR mRNAs and their mouse orthologues relative to ACTB, GAPDH, PPIA, TBP and TFRC are presented in Supplementary Figure 1.

The similarities and differences in islet GPCR mRNA expression between human islets and the two mouse strains are illustrated in Fig. 2d,e. The analysis was carried out with all detected GPCRs, including GPCRs present only at trace level (Fig. 2d) and also with only those GPCRs with mRNA expression above trace level (Fig. 2e), as these are more likely to affect islet function. A core set of 189 GPCR mRNAs (53.7% of all human GPCRs) were expressed in both human and ICR/C57 mouse islets (Fig. 2d). 9.9% of all GPCR mRNAs (35 GPCRs) were found exclusively in human islets, and 63 receptors (18.5% of all investigated GPCRs) were expressed exclusively in mouse islets and not in human islets (Fig. 2d). When only GPCR mRNAs present above trace level were examined, a core set of 121 GPCR mRNAs (34.4% of all GPCRs) was expressed in both human and ICR/C57 mouse islets.
islets. 20.7% of all GPCRs (71 receptors) were expressed above trace level only in human islets, whereas 48 receptors (14.1%) were expressed above trace level only in mouse islets (Fig. 2e).

There was a reasonable similarity in the GPCR mRNA expression profiles of human and mouse islets (ICR, r²: 0.36; C57, r²: 0.31), but the inter-species differences were much greater than the small inter-strain differences, as expected. Our data indicate that ~36% of all GPCRs screened were expressed above trace levels in both human and mouse islets, and a core set of 121 GPCR mRNAs were expressed by islets of both species (Fig. 3a,b). The enrichment of mRNAs encoding these 121 GPCRs in human and mouse islets was determined relative to mRNA expression levels of the five reference genes to allow direct comparison of GPCR expression patterns between species (Fig. 4a,b). This indicated that although a large number of GPCR mRNAs are expressed by both human and mouse islets, there are significant species differences in their abundance. Compared to human islets, mRNAs encoding 68 GPCRs were at least 3 fold enriched in mouse islets, and 17 of these GPCRs (Adra2a, CalCrl, Cckar, Chrm3, Fzd3, Galr1, Gipr, Gpl1r, Gpr116, Gpr125, Gpr158, Gpr56, Gprc5c, Lgr4, Oxttr, Ptger3, Vipr1) were also among the 25 most abundant mouse islet GPCR mRNAs (Fig. 3a,b). Four GPCR mRNAs (GPR44, GPR126, C5AR1, GPR135) were >3 fold enriched in human islets compared to mouse islets (Fig. 3a,b). Overall, 72 of the 121 islet GPCR mRNAs expressed by both human and mouse islets differed <3 fold in mRNA expression.

Approximately 10% of all GPCR mRNAs (ICR: 38 GPCRs; C57: 35 GPCRs; 43 GPCRs in total) were expressed exclusively in mouse islets, with either trace or no expression at all in human islets. In particular, mRNAs encoding the GAL1, (GALR1), GAL2, (GALR2) and GAL3, CELSR1, adenosine A1 (ADORA1), LPA1 (LPR6) and GPR85 receptors were abundantly expressed in mouse islets but were either absent or expressed at very low level in human islets (Supplementary Figure 1). Similarly, we found that 81 GPCR mRNAs were preferentially expressed in human islets and were absent or expressed only at trace level in islets isolated from one or both of the mouse strains. The most abundant of the human islet-specific mRNAs were those encoding the 5-HT1F (HTR1F), secretin (SCTR), α1b adrenergic (ADRA2C), sst1 (SSTR1) and mGlut1 (GRM4) receptors (Supplementary Figure 1). In addition, three human-specific GPCR genes (GPR148, OXER1 and P2RY8), which do not exist in the mouse genome, were also expressed above trace levels in human islets (Fig. 5).

**Functional validation of human or mouse islet-specific GPCR expression.** Selective expression of A1 receptors by mouse islets was confirmed by experiments using the A1 receptor agonist MRS 5698, which caused significant inhibition of glucose-induced insulin secretion from mouse, but not human islets. Appropriate Gi-coupling in human islets was confirmed by the use of the α1b-adrenergic-selective agonist clonidine, which inhibited insulin secretion, as expected (Fig. 6b,c). Similarly, activation of the highly expressed galanin receptors on mouse islets by exposure to mouse galanin-(2−29) resulted in concentration-dependent inhibition of insulin secretion, whereas human galanin-(1−30) did not significantly affect insulin secretion from human islets (Fig. 7a,b). The G1-coupled sst1 (SSTR1) receptor mRNA was abundantly expressed in human islets, but only present at very low levels in mouse islets. Functional evaluation of the sst1 receptor agonist CH 275 indicated that it significantly inhibited insulin secretion from human islets, but it had no effect on insulin release from mouse islets (Fig. 8a,b).

**Discussion**

A recent review analysing drugs acting on human therapeutic targets indicated that GPCRs are the largest class of targets for the development of new pharmaceutical products. However, despite the use of GPCR-targeted drugs to treat a variety of clinical conditions such as asthma and hypertension only the GLP-1 receptor has been used successfully in treating T2D. This limited application of GPCR-based therapies for T2D is due, in part, to the poor functional characterisation of the majority of islet-expressed GPCRs and this is further exacerbated by the insufficient availability of human islets for identifying functional effects of GPCRs that are known to be expressed by islets. Rodent islets, in particular those isolated from mice, are therefore often relied upon as translational models. Despite this, there are significant differences between rodent and human islets which may impact on the choice of model for functional characterisations. For example, C57 mouse islets did not express the sst3 receptor (Sstr3) so islets from this strain would not be suitable for characterising somatostatin signalling through this receptor subtype. Conversely, the orphan GPCR Gpr45 is expressed at moderately high levels in C57 islets but only at very low levels in ICR islets. This suggests that islets from C57 mice would be the model of choice for identifying the role of this receptor once appropriate tools are available, although relevance to the human situation is very low since GPR45 mRNA is only expressed at trace levels by human islets. In addition,
Figure 3. (a,b) Mean relative mRNA expression of human GPCRs in human islets and mouse GPCR orthologues in islets from ICR (a) and C57 (b) mice. Data are presented as mean GPCR mRNA expression ± SEM relative to the reference genes ACTB, GAPDH, PPIA, TBP and TFRC. Data generated using non-pooled islet RNA from four ICR and four C57 mice and four non-pooled human islet preparations. Insert panels A and B represent enlarged areas of the scatter plots, added to allow visualisation of individual GPCR mRNAs. *: excluding bitter taste receptors (TAS2Rs).
although eight out of the ten most highly expressed GPCR mRNAs were common to C57 and ICR islets, Fzd3 and Gabbr2 were higher in ICR islets while Galr3 and Gipr were higher in C57 islets. Despite this, there was still a high similarity of expression levels of Fzd3, Gabbr2, Galr3 and Gipr between ICR and C57 islets, as shown in Supplementary Figure 1.

There have been earlier comparisons of gene expression in mouse and human islets12–14, but no focused study aimed at identifying similarities and differences in GPCR mRNA expression in human and mouse islets has been reported. Understanding which GPCRs are present on human islets, and if mouse islets can be used as a translational model system, are essential for evaluating whether particular islet GPCRs are potential novel targets for the development of new diabetes therapeutics. Interestingly, we have shown that GLP-1 receptors are in the top 10 GPCRs expressed by both mouse and human islets, so discoveries of the beneficial effects of GLP-1 agonists on glucose homeostasis in mice are directly translatable to the human situation, as is seen with the successful use

Figure 4. (a,b) Species enrichment of the 121 islet GPCR mRNAs expressed above trace level in both human and mouse islets. Mean ICR and C57 GPCR mRNA expression levels were compared to the mRNA expression of human islet GPCRs. mRNAs encoding 68 GPCRs were >3 fold enriched in mouse islets (a), 17 of these GPCRs (Adra2a, CalCrl, Cckar, Chrm3, Fzd3, Galr1, Gipr, Glp1r, Gpr116, Gpr125, Gpr158, Gpr56, Gprc5c, Lgr4, Oxt, Ptger3, Vipr1) are also among the 25 most abundant mouse islet GPCR mRNAs (highlighted with * in figure a). Four GPCR mRNAs were >3 fold enriched in human islets (b). Data are presented as a ratio of the mean GPCR expression relative to the reference genes ACTB, GAPDH, PPIA, TBP and TFRC in human and mouse islets (i.e. mean of GPCR expression in ICR and C57 islets), and was generated using non-pooled islet RNA from four ICR and four C57 mice and four non-pooled human islet preparations.
of stable GLP-1 analogues as T2D therapies. We also found that FFAR1, which codes for a GPCR that is activated by long chain fatty acids, is highly expressed in human and mouse islets. FFAR1 agonists have been considered as novel therapies for T2D, but the development of a promising candidate, TAK-875,25 has been discontinued because of adverse effects on the liver.26

We have also identified that several well-characterised GPCRs (CASR, GPRC5B, GPR119, F2RL1), which are either current drug targets or under evaluation as potential diabetes therapeutic targets, are highly expressed in both human and mouse islets. In addition, other highly expressed human islet GPCRs (e.g. ADGRG1 [GPR56], LPHN1, ELTD1) provide scope for further analysis, and the observation that ADGRG1 is also highly expressed in mouse islets indicates that these can be used with confidence to identify signalling downstream of this receptor. An important role for ADGRG1 in β-cell function and survival has recently been reported,27 whereas the role of ELTD1 and LPHN1 in islet function remain unknown.

Our qPCR analyses have also indicated that a large number of GPCR mRNAs were expressed at very low levels (<0.001% of the mean mRNA expression of the five reference genes ACTB, GAPDH, PPIA, TBP and TFRC) in both human and mouse islets. At such low levels, it is not possible to accurately quantify the mRNA expression, as it falls outside of the linear range of detection for the QuantiTect qPCR primer assays. These mRNAs are

Figure 5. Relative expression in human islets of GPCRs that are absent in the mouse genome. Data are presented as mean ± SEM GPCR expression relative to the reference genes ACTB, GAPDH, PPIA, TBP and TFRC. n = four human islet donors. T denotes trace expression.

Figure 6. Confirmation of mouse islet-specific expression and function of the A3 (Adora3) receptor. The A3 receptor agonist MRS 5698 had no effect on insulin secretion from human islets (a), but significantly inhibited glucose-stimulated insulin secretion from mouse islets (b). The Gα coupled control agonist clonidine had significant inhibitory effects in both mouse and human islets. *p < 0.05; ***p < 0.001 versus secretion at 20 mM glucose.


nevertheless present in human and mouse islets, albeit at low copy numbers, and they are likely to be translated into GPCR proteins. It is difficult to evaluate the physiological impact of these low abundance receptor proteins on islet function. In fact, mRNAs encoding receptors present at trace levels are expressed at approximately 16,000–45,000 fold lower concentrations than the mRNA encoding the most abundant islet GPCR, ADGRG1 [GPR56]. We cannot exclude that GPCR mRNAs present at trace level may be transcribed into proteins capable of influencing islet function, but based on the assumption that the mRNAs encoding these receptors are expressed at very low levels, and therefore likely to result in low levels of GPCR protein, we hypothesise that GPCRs with mRNA expression at trace level in islets are less likely to have a major impact on islet function compared to GPCRs with more abundant mRNA expression. This is exemplified by our functional studies on the inhibitory effects of the A3 and galanin receptors on insulin secretion: mRNAs encoding the A3, GAL1 and GAL3 receptor mRNAs are highly expressed in mouse islets, but absent or only present at trace levels in human islets, and this

Figure 7. The effect on insulin secretion by the galanin receptor agonist galanin in human (a) and mouse (b) islets. Human galanin-(1–30) had no effect on insulin secretion from human islets, whereas insulin secretion from mouse islets was significantly inhibited by mouse galanin-(2–29) (b). n = 8 islets in each treatment group. *p < 0.05; **p < 0.01; ***p < 0.001.

Figure 8. The effect of the Sst1 receptor agonist CH 275 on the secretion of insulin from human (a) and mouse (b) islets at 2 and 20 mM glucose. A dose-dependent inhibition of insulin secretion by CH 275 was observed in human islets (a), whereas CH275 had no effect on insulin secretion from mouse islets (b). *p < 0.05; ***p < 0.001.
in turn translated into a clear inhibitory effect on insulin secretion following activation of the GAL1/GAL3 or A3 receptors by exogenous agonists in mouse islets, while there was no significant effect on insulin secretion from human islets. Similar species-specific functional effects were observed for activation of the sst1 receptor, which is abundantly expressed in human islets but only present at very low levels in mouse islets. Consequently, in human islets, activation of the Gq-coupled sst1 receptor by the selective sst1 receptor agonist CH 275 led to inhibition of insulin secretion, whereas no effects on mouse islet insulin secretion were observed.

The importance of determining the expression by human islets of GPCRs that have been investigated in rodent studies is illustrated by earlier studies where there is a mismatch between GPCR expression by mouse and human islets. For example, it has been reported that mRNA expression of the trace amine receptor Taar1 is restricted to islets in mice, suggesting that this receptor might be a potential target for novel diabetes therapeutics. However, subsequent studies by ourselves and others using both qPCR and RNA-sequencing have shown that Taar1 is expressed at very low levels in human islets, thus making it a much less likely target for islet GPCR-focused therapeutics. Similarly, the abundant expression of several other mouse islet GPCRs - A1 (Adora3), Celsr1, GAL1 (Galr1), GAL2 (Galr2), GAL3 (Galr3), Gpr158, Lpar6, Slpr3 and OT (Oxtr) - can also be ruled out as potential human islet GPCR drug targets based on their low (or absent) expression in human islets.

In summary, in this study, we have systematically compared the expression of all known human GPCR mRNAs and their mouse orthologues in human and mouse islets and mapped the similarities and differences in islet GPCR mRNA expression between the two species. We have demonstrated that there is a common expression of a number of islet GPCRs between mouse and man, which allows mouse islets to be used as appropriate surrogates for human islets when investigating the function of these GPCRs in islets. However, we have also identified that significant differences do exist in GPCR expression between mouse and human islets, so care should be taken in the choice of model for functional analyses to ensure that data obtained using mouse islets are relevant to the human situation. Overall, the data presented here provide an essential resource for the translation of mouse islet functional data to the human islet context, which will facilitate the identification of islet GPCRs for evaluation as potential novel drug targets for diabetes.

Research Design and Methods
Islet isolation and culture. Islets were isolated from 10–12 week old male mice of the inbred C57BL/6 (C57; Charles River) and outbred ICR (Harlan) strains by collagenase digestion of the exocrine pancreas. All animal procedures were approved by the King’s College London Ethics Committee and carried out in accordance with the UK Home Office Animals (Scientific Procedures) Act 1986.

Human islets were isolated from non-diabetic organ donors at the King’s College London Human Islet Isolation Unit with appropriate ethical approval and donor consent for research (Protocol number 01–082, Human Islet Isolation and Research). An assent form was completed by a relative of the pancreas donor for all islets used for research, and all experiments carried out on human islets were performed in accordance with the relevant guidelines and regulations as set out by the King’s College London Ethics Committee.

Isolated mouse and human islets were maintained in culture overnight (mouse: RPMI 1640; human: CMRL) at 37 °C, 5% CO2 before extraction of RNA.

RNA extraction and quantitative real-time PCR. Olfactory, pseudogene and vomeronasal GPCRs were not included in the study and the bitter taste receptors (TAS2Rs) were also excluded as the nomenclature identifying the exact mouse TAS2R orthologues is very unclear, often with identical gene symbols being used for several different mouse bitter taste receptor genes. Total non-pooled RNA from ~200 islets isolated from four C57 and four ICR mice and from four non-diabetic human islet donors (2 male and 2 female, donor age 49.5 ± 3.5 years old, BMI 28.2 ± 2.3 kg/m2) was isolated using a modified TRIzol protocol followed by RNA clean-up on RNeasy MiniElute columns (Qiagen). 500 ng of islet total RNA from each mouse or human donor was converted into cDNA using the TaqMan RT-PCR kit (Life Technologies) as described elsewhere. Quantitative real-time PCR (qPCR) with Qiagen QuantiTect SYBR Green mouse or human primer assays was performed using islet cDNAs to quantify the expression of 352 non-olfactory, non-vomeronasal, non-bitter taste human GPCRs and 341 mouse orthologues as described in detail elsewhere. For both mouse and human islets, GPCR mRNA levels were expressed relative to the reference genes ACTB, GAPDH, PPIA, TBP and TFRC. All GPCR and reference gene primer efficiency [E] values were in the range of 1.85–2.15. For all GPCR and reference gene quantifications, template cDNAs were diluted in such a way that all quantified genes returned Ct values < 30. Genes expressed < 0.001% of the mean mRNA level of the five reference genes were considered to be present only at trace level, as their expression was less than the lower limit of linear quantification of the QuantiTect primer assays. The human and mouse qPCR primers used for amplifications are listed in Supplementary Table S2. Enrichment of GPCR mRNA expression in human islets were calculated using the formula below:

\[
\text{Enrichment of GPCR expression} = \frac{\text{Mean mouse islet GPCR expression relative to reference genes}}{\text{Mean human islet GPCR expression relative to reference genes in ICR and C57 mouse islets}}
\]

For enrichment of GPCR expression in mouse islets, the inverse of the above formula was used.

Insulin secretion. Human and mouse isolated islets were cultured overnight in either CMRL or RPMI with 11 mM glucose supplemented with 10% fetal bovine serum. After a 1-h pre-incubation in physiological salt solution containing 2 mM glucose, insulin release was assessed by static incubation. Briefly, groups of five size-matched islets were hand-picked into 1.5 ml microcentrifuge tubes and incubated for 1 hour in a physiological salt solution at 37 °C in the absence or presence of the A3 receptor-selective agonist MRS 5698, human
galanin-(1–30), mouse galanin-(2–29) or the sst1 agonist CH 275 (Tocris Bioscience). Insulin secreted into the supernatant was quantified by radioimmunoassay as described elsewhere34.

References
1. Amisten, S., Salehi, A., Rorsman, P., Jones, P. M. & Persaud, S. J. An atlas and functional analysis of G-protein coupled receptors in human islets of Langerhans. Pharmacology & therapeutics 139, 359–391 (2013).
2. Ahren, B. Autonomic regulation of islet hormone secretion—implications for health and disease. Diabetesologia 43, 393–410 (2000).
3. Jones, P. M. P. S. Textbook of Diabetes. In: Textbook of Diabetes (ed=(eds Holt G, Flyvberg). Blackwell Scientific Press, UK (2010).
4. De Marinis, Y. Z. et al. GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+-channel-dependent exocytosis. Cell Metab 11, 543–553 (2010).
5. Tuch, B. E. Clinical use of GLP-1 agonists and DPP4 inhibitors. Pancreatology 16, 8–9 (2016).
6. Oh, S. Y. & Olefsky, J. M. G protein-coupled receptors as targets for anti-diabetic therapeutics. Nat Rev Drug Discov 15, 161–172 (2016).
7. Soni, A., Amisten, S., Rorsman, P. & Salehi, A. GPRC5B a putative glutamate-receptor candidate is negative modulator of insulin secretion. Biochem Biophys Res Commun 441, 643–648 (2013).
8. Regard, J. R., Sato, J. T. & Couglin, S. R. Anatomical profiling of G protein-coupled receptor expression. Cell 135, 561–571 (2008).
9. Regard, J. R. et al. Probing cell type-specific functions of Gi in vivo identifies GPRC regulators of insulin secretion. J Clin Invest 117, 4034–4043 (2007).
10. Cabrera, O., Berman, D. M., Kenyon, N. S., Ricordi, C., Berggren, P. O. & Caicedo, A. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc Natl Acad Sci USA 103, 2334–2339 (2006).
11. Kim, A., Miller, K., Jo, J., Kilnikov, G., Wojcik, P. & Hara, M. Islet architecture: A comparative study. Islets 1, 129–136 (2009).
12. Dai, C. et al. Islet-enriched gene expression and glucose-induced insulin secretion in human and mouse islets. Diabetesologia 55, 707–718 (2012).
13. Benner, C., van der Meulen, T., Caceres, E., Tigi, K., Donaldson, C. J. & Huisng, M. O. The transcriptional landscape of mouse beta cells compared to human beta cells reveals notable species differences in long non-coding RNA and protein-coding gene expression. BMC Genomics 15, 620 (2014).
14. Kutlu, B. et al. Detailed transcriptome atlas of the pancreatic beta cell. BMC Med Genomics 2, 3 (2009).
15. Lacey, R. J. et al. Differential effects of beta-adrenergic agonists on insulin secretion from pancreatic islets isolated from rat and man. J Mol Endocrinol 5, 49–54 (1990).
16. Ramracheya, R. D. et al. Function and expression of melatonin receptors on human pancreatic islets. J Pineal Res 44, 273–279 (2008).
17. Li, G. D. et al. Extracellular ATP causes Ca2+(-)-dependent and -independent insulin secretion in RINm5F cells. Phospholipase C mediates Ca2+ mobilization but not Ca2+ influx and membrane depolarization. J Biol Chem 266, 3449–3457 (1991).
18. Squires, P. E., James, R. F., London, N. J. & Dunne, M. J. ATP-induced intracellular Ca2+ signals in isolated human insulin-secreting cells. Pflugers Arch 427, 181–183 (1994).
19. Gallwitz, B. Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents. Drugs 71, 1675–1688 (2011).
20. Rask-Andersen, M., Almen, M. S. & Schioth, H. B. Trends in the exploitation of novel drug targets. Nat Rev Drug Discov 10, 579–590 (2011).
21. Amisten, S. Quantification of the mRNA expression of G protein-coupled receptors in human adipose tissue. Methods Cell Biol 132, 73–103 (2016).
22. Nagalakshmi, U. et al. The transcriptional landscape of the yeast genome defined by RNA sequencing. Science 320, 1344–1349 (2008).
23. Zhao, S., Fung-Leung, W. P., Bittner, A., Ngo, K. & Liu, X. Comparison of RNA-Seq and microarray in transcriptome profiling of activated T cells. PLoS One 9, e87644 (2014).
24. Marioni, J. C., Mason, C. E., Mane, S. M., Stephens, M. & Gilad, Y. RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. Genome Res 18, 1509–1517 (2008).
25. Srivastava, A. et al. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. Nature 513, 124–127 (2014).
26. Li, X., Zhong, K., Guo, Z., Zhong, D. & Chen, X. Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury. Drug Metab Dispos 43, 1751–1759 (2015).
27. Duner, P. et al. Adhesion G-protein coupled receptor G1 (ADGRG1/GPR56) and pancreatic beta-cell function. J Clin Endocrinol Metab 201618884 (2016).
28. Pasquale, L. et al. Pancreatic islet enhancer clusters enriched in type 2 diabetes risk-associated variants. Nat Genet 46, 136–143 (2014).
29. Liu, B. et al. The novel chemo kinase receptor, G-protein-coupled receptor 75, is expressed by islets and is coupled to stimulation of insulin secretion and improved glucose homeostasis. Diabetesologia 56, 2467–2476 (2013).
30. Huang, G. C. et al. The development of new density gradient media for purifying human islets and islet-quality assessments. Transplantation 77, 143–145 (2004).
31. Amisten, S., Braun, O. O., Bengtsson, A. & Erlinge, D. Gene expression profiling for the identification of G-protein coupled receptors in human platelets. Thromb Res 122, 47–57 (2008).
32. Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29, e45 (2001).
33. Gey, G. O. & Gey, M. K. GM. The maintenance of human normal cells and tumor cells in continuous culture: I. Preliminary report: cultivation of mesoblastic tumors and normal tissue and notes on methods of cultivation. J Exp Med 273–279 (1936).
34. Jones, P. M., Salmon, D. M. & Howell, S. L. Protein phosphorylation in electrically permeabilized islets of Langerhans. Effects of Ca2+, cyclic AMP, a phosphol ester and noradrenaline. Biochem J 254, 397–403 (1988).

Acknowledgements
We are grateful to the relatives of organ donors for human pancreases for research. This study was supported by grants from the EFSDD/Boehringer-Ingelheim Research Programme and a Diabetes UK RD Lawrence Fellowship to Stefan Amisten (11/004172).

Author Contributions
The study was designed by S.A., P.A., R.H., A.S. and S.J.P. Data were collected and analysed by S.A., R.H., P.A., I.R.M., F.P. and B.L. G.C.H. and M.Z. provided the isolated human islets of Langerhans. The article was drafted by S.A. and S.J.P. All authors revised the article critically for important intellectual content. All authors gave their final approval of the current version to be published. S.A. and S.J.P. take responsibility for the contents of the article.
